Article ; Online: Management of Cystoid Macular Edema After Vitrectomy for Proliferative Vitreoretinopathy.
Ophthalmic surgery, lasers & imaging retina
2020 Volume 51, Issue 8, Page(s) 436–443
Abstract: Background and objective: To assess therapies for cystoid macular edema (CME) following pars plana vitrectomy for proliferative vitreoretinopathy (PVR).: Patients and methods: Retrospective analysis of 42 eyes developing CME after PVR surgery. ... ...
Abstract | Background and objective: To assess therapies for cystoid macular edema (CME) following pars plana vitrectomy for proliferative vitreoretinopathy (PVR). Patients and methods: Retrospective analysis of 42 eyes developing CME after PVR surgery. Treatments included topical therapy, sub-Tenon's triamcinolone acetonide (STTA), intravitreal bevacizumab and combinations thereof. Best-corrected visual acuity (BCVA) as well as central subfield thickness (CST) were tracked. Results: Mean Snellen BCVA improved from 20/598 to 20/297 (logMAR change -0.21; confidence interval [CI], -0.39 to -0.03; P = .03). Mean CST improved from 448 µm to 260 µm (CI, -248.70 to -126.06; P < 0.01). There was no difference in efficacy between treatment subgroups (analysis of variance, P = 0.16, 0.43), but STTA yielded statistically significant improvement in both categories (CI, -0.79 to -0.11; P = 0.01; and CI, -333.74 to 166.51; P < .01). Conclusions: Treatment of CME following PVR surgery is possible with a variety of different options. STTA appears to yield anatomical and visual improvement. [Ophthalmic Surg Lasers Imaging Retina. 2020;51:436-443.]. |
---|---|
MeSH term(s) | Aged ; Angiogenesis Inhibitors/administration & dosage ; Bevacizumab/administration & dosage ; Disease Management ; Female ; Follow-Up Studies ; Glucocorticoids/administration & dosage ; Humans ; Intravitreal Injections ; Macular Edema/diagnosis ; Macular Edema/etiology ; Macular Edema/therapy ; Male ; Receptors, Vascular Endothelial Growth Factor/antagonists & inhibitors ; Retrospective Studies ; Tomography, Optical Coherence ; Treatment Outcome ; Triamcinolone Acetonide/administration & dosage ; Visual Acuity ; Vitrectomy/adverse effects ; Vitreoretinopathy, Proliferative/surgery |
Chemical Substances | Angiogenesis Inhibitors ; Glucocorticoids ; Bevacizumab (2S9ZZM9Q9V) ; Receptors, Vascular Endothelial Growth Factor (EC 2.7.10.1) ; Triamcinolone Acetonide (F446C597KA) |
Language | English |
Publishing date | 2020-08-18 |
Publishing country | United States |
Document type | Journal Article |
ZDB-ID | 2701167-7 |
ISSN | 2325-8179 ; 2325-8160 |
ISSN (online) | 2325-8179 |
ISSN | 2325-8160 |
DOI | 10.3928/23258160-20200804-03 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.A 756: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.